糠酸氟替卡松、三氟甲磺酸维兰特罗及其联合制剂治疗慢性阻塞性肺疾病研究进展

摘要

Fluticasone is a novel corticosteroid with potent glucocorticoid activity. Vilanterol is an orally inhaled long-acting β2 agonist (LAB A). This review describes the evaluation of clinical application of fluticasone furoate, vilanterol trifenatate and Relovair in the patients with chronic obstructive pulmonary disease (COPD). Relovair, a novel inhaled corticosteroid/LABA formulation, can further improve outcomes for patients. It is likely a promising advance in the treatment of COPD.%氟替卡松是一种新型的强效糖皮质激素,维兰特罗为经口腔吸入型选择性长效β2受体激动剂(LABA).本文综述糠酸氟替卡松、三氟甲磺酸维兰特罗及糠酸氟替卡松/三氟甲磺酸维兰特罗干粉吸入剂(Relovair)在慢性阻塞性肺疾病(COPD)患者中的临床应用评价.新的吸入型糖皮质激素/LABA复合制剂Relovair可进一步改善患者的治疗效果,在COPD治疗中具有广阔的应用前景.